{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:40:14Z","timestamp":1781134814636,"version":"3.54.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T00:00:00Z","timestamp":1311206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Clin Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>One of the most critical problems about antimicrobial therapy is the increasing resistance to antibiotics. Previous studies have shown that there is a direct relation between erroneous prescription, dosage, route, duration of the therapy and the antibiotics resistance. Other important point is the uncertainty about the quality of the prescribed medicines. Some physicians believe that generic drugs are not as effective as innovator ones, so it is very important to have evidence that shows that all commercialized drugs are suitable for therapeutic use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Microbial assays were used to establish the potency, the Minimal Inhibitory Concentrations (MICs), the Minimal Bactericidal Concentration (MBCs), the critical concentrations, and the production of spontaneous mutants that are resistant to vancomycin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The microbial assay was validated in order to determine the Vancomycin potency of the tasted samples. All the products showed that have potency values between 90 - 115% (USP requirement). The products behave similarly because the MICs, The MBCs, the critical concentrations, the critical concentrations ratios between standard and samples, and the production of spontaneous mutants don't have significant differences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>All products analyzed by microbiological tests, show that both trademarks and generics do not have statistical variability and the answer of antimicrobial activity Show also that they are pharmaceutical equivalents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6904-11-9","type":"journal-article","created":{"date-parts":[[2011,7,22]],"date-time":"2011-07-22T06:15:39Z","timestamp":1311315339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products of vancomycin"],"prefix":"10.1186","volume":"11","author":[{"given":"Jorge A","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelberto","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,21]]},"reference":[{"key":"106_CR1","unstructured":"CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, NATIONAL INSTITUTES OF HEALTH. A Public Health Action Plan to Combat Antimicrobial Resistance, [http:\/\/www.cdc.gov\/drugresistance\/pdf\/2010\/Interagency-Action-Plan-PreClearance-03-2011.pdf]"},{"key":"106_CR2","unstructured":"THE UNITED STATES PHARMACOPOEIA. XXVII. Biological test and assays. 1883, Pharmacopoeia Convention Inc Bronx New York USA, 358-"},{"key":"106_CR3","unstructured":"INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Validation of Analytical Procedures: Text and Methodology. Q2 (R1). Current Step 4 version. Parent Guideline dated 27 October 1994 (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005). 1994, October (Complementary Guideline on Methodology dated 6 November 1996 incorporated in November 2005)"},{"key":"106_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2007.12.010","volume":"61","author":"RN Jones","year":"2008","unstructured":"Jones RN, Fritsche TR, Moet GJ: In vitro potency evaluations of various piperacillin\/tazobactam generic products compared with the contemporary branded (Zosyn\u00ae, Wyeth) formulation. Diagnostic Microbiology and Infectious Disease. 2008, 61: 76-79. 10.1016\/j.diagmicrobio.2007.12.010.","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"106_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.diagmicrobio.2009.06.012","volume":"65","author":"Gary J Moeta","year":"2009","unstructured":"Moeta Gary, Wattersa Amy, Sadera Helio, Jonesx Ronald: Expanded studies of piperacillin\/Tazobactam formulations: variations among branded product lots and assessment of 46 generics lots. Diagnostic Microbiology and Infectious Disease. 2009, 65: 319-322. 10.1016\/j.diagmicrobio.2009.06.012.","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"key":"106_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6904-9-1","volume":"9","author":"AF Zuluaga","year":"2009","unstructured":"Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O: Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clinical Pharmacology. 2009, 9: 1-","journal-title":"BMC Clinical Pharmacology"},{"key":"106_CR7","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1128\/AAC.01044-09","volume":"54","author":"O Vesga","year":"2010","unstructured":"Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga F: Generic products of vancomycin fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother. 2010, 54: 3271-3279. 10.1128\/AAC.01044-09.","journal-title":"Antimicrob Agents Chemother"},{"key":"106_CR8","volume-title":"Revista Colombiana de Ciencias Qu\u00edmico-Farmac\u00e9uticas","author":"P Melendez","year":"2005","unstructured":"Melendez P, Diaz J, Silva E, Gonzales P, Gonzalez P, Moreno E, Amaya P, Serrato N, Saenz E: Estudio comparativo de la actividad antimicrobiana de diferentes presentaciones comerciales de antibi\u00f3ticos de administraci\u00f3n intravenosa a trav\u00e9s de m\u00e9todos in vitro. Revista Colombiana de Ciencias Qu\u00edmico-Farmac\u00e9uticas. 2005, 34:"},{"key":"106_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6904-10-3","volume":"10","author":"E Silva","year":"2010","unstructured":"Silva E, Diaz JA, Arias MJ, Hernadez AP, De La Torre A: Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration. BMC Clinical Pharmacology. 2010, 10: 3-","journal-title":"BMC Clinical Pharmacology"},{"key":"106_CR10","unstructured":"Lorian V, (Ed.): Antibiotics in Laboratory Medicine. 1980, Williams & Wilkins. Baltimore, 95-98."}],"container-title":["BMC Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-11-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6904-11-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-11-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6904-11-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:31:54Z","timestamp":1630510314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/1472-6904-11-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,21]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["106"],"URL":"https:\/\/doi.org\/10.1186\/1472-6904-11-9","relation":{},"ISSN":["1472-6904"],"issn-type":[{"value":"1472-6904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,21]]},"assertion":[{"value":"13 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"9"}}